AXIM Biotechnologies Inc AXIM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AXIM is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.02
- Day Range
- $0.01–0.02
- 52-Week Range
- $0.01–0.04
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $3.54 Mil
- Volume/Avg
- 724,896 / 541,249
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 86.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.aximbiotech.com
Valuation
|
Metric
|
AXIM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 86.21 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AXIM
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.01 |
Interest Coverage | −5.33 |
Quick Ratio
AXIM
Profitability
|
Metric
|
AXIM
|
|---|---|
Return on Assets (Normalized) | −92.85% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AXIM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pgpzpwrvzw | Dzxz | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xmktwmtl | Wjrzph | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vhtyggzd | Htrdpzv | $98.8 Bil | |
MRNA
| Moderna Inc | Wtlbynzb | Qrdk | $38.8 Bil | |
ARGX
| argenx SE ADR | Vgsbmzkd | Smkx | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Ljwffgn | Qtkws | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cmkkyrbc | Xwmyfb | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hdstfzgdx | Xzrgvbc | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bpkcnlsg | Lmjxvfy | $12.4 Bil | |
INCY
| Incyte Corp | Fhspgps | Kptgnq | $11.9 Bil |